You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Novartis to fund oral skin cancer drug
South Korean Multichannel Industry To Survive With Right Strategies
South Korean Telcos Drive Next Wave Of Growth Through Home IoT Opportunities
Mining Exploration Insights: Financing Falls To 8-Month Low In October
Taking Advantage of Issuance Trends in 2020
Ligand Pharmaceuticals Inc. is partnering with Novartis AG to develop a liquid formulation of Trametinib using its Captisol technology.
Trametinib is used to treat a certain type of skin cancer with Captisol designed to optimize the solubility and stability of drugs.
Novartis will fund the program in exchange for commercialization rights. Ligand will receive an undisclosed license fee as well as royalties on future sales as a result of the agreement.